# SFA Therapeutics

**Source:** https://geo.sig.ai/brands/sfa-therapeutics  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Emerging  
**Website:** sfatherapeutics.com  
**Last Updated:** 2026-04-14

## Summary

Oral Treg modulator biotech with positive Phase 1b psoriasis safety data; $9.13M raised from Savantus Ventures competing in autoimmune therapy with a restore-immune-balance mechanism.

## Company Overview

SFA Therapeutics is a Philadelphia-based clinical-stage biotech developing oral small molecule drugs that modulate regulatory T cells (Tregs) — the immune system's natural suppressor cells — to restore immune homeostasis in autoimmune diseases and cancer without the broad immunosuppression that existing biologics and small molecule therapies cause. The company raised $9.13 million from investors including Savantus Ventures and Ben Franklin Technology Partners, announced positive Phase 1b safety data for SFA-002 in psoriasis in March 2025, and received a 2025 Prix Galien USA Best Startup award nomination.

SFA Therapeutics' Treg modulator approach targets a fundamentally different mechanism than approved autoimmune drugs: rather than blocking specific inflammatory cytokines (like TNF inhibitors) or broadly depleting immune cells (like many chemotherapy agents), SFA-002 and related compounds selectively increase the activity or number of Tregs — the cells that naturally regulate immune responses and prevent autoimmunity. This "restore natural balance" mechanism could potentially treat autoimmune diseases while preserving normal immune function more completely than current approaches.

In 2025, SFA competes in the autoimmune drug discovery and Treg biology space with Sonoma Biotherapeutics, Quell Therapeutics (Treg cell therapy), Cue Biopharma (Treg-stimulating biologics), and the established small molecule immunology companies (AbbVie with Humira/Skyrizi, Pfizer with Xeljanz) for autoimmune disease treatment. The Treg biology field has generated significant scientific interest — if oral small molecules can selectively activate Tregs without causing immunosuppression or infection risk, the therapeutic window for autoimmune diseases could be dramatically expanded. Psoriasis Phase 1b safety data is the first human clinical validation of the approach. The 2025 strategy focuses on advancing SFA-002 through Phase 2 proof-of-concept trials in psoriasis, exploring additional autoimmune indications (rheumatoid arthritis, inflammatory bowel disease), and building the chemistry platform for next-generation Treg modulators.

## Frequently Asked Questions

### What is SFA Therapeutics?
SFA Therapeutics is a Philadelphia-based clinical-stage biopharmaceutical company that develops oral small-molecule biosynthetic Treg modulators for treating autoimmune diseases, chronic inflammatory conditions, and cancer. The company focuses on restoring durable immune homeostasis without suppressing overall immune response.

### What products and services does SFA Therapeutics offer?
SFA Therapeutics offers first-in-class Treg modulators, oral small-molecule therapeutics for autoimmune disease treatments, chronic inflammation therapies, and cancer immunomodulation. Their lead product, SFA-002, is currently in Phase 1b clinical trials for psoriasis treatment.

### Who are SFA Therapeutics' target customers?
SFA Therapeutics serves pharmaceutical companies, biotech researchers, and patients requiring immune system regulation therapies for autoimmune conditions and cancer globally.

### When was SFA Therapeutics founded?
SFA Therapeutics was founded in 2016 and participated in Y Combinator's S21 batch.

### Where is SFA Therapeutics located?
SFA Therapeutics is based in Philadelphia, Pennsylvania.

### How much funding has SFA Therapeutics raised?
SFA Therapeutics has raised $9.13M in total funding from investors including Savantus Ventures, Ben Franklin Technology Partners, North South Ventures, Asymmetry Ventures, Acequia Capital, and 9 others. Ben Franklin Technology Partners made an additional investment in February 2024.

### What are SFA Therapeutics' key achievements?
SFA Therapeutics announced positive Phase 1b data for SFA-002 in mild-to-moderate psoriasis in March 2025, meeting the primary safety endpoint with no treatment-related adverse events. The company was nominated for the 2025 Prix Galien USA Best Startup award in August 2025.

### What technology approach does SFA Therapeutics use?
SFA Therapeutics uses oral small-molecule biosynthetic Treg modulators to restore durable immune homeostasis and correct immune dysregulation without suppressing overall immune response. This first-in-class approach targets immune balance restoration for treating autoimmune diseases, chronic inflammation, and cancer.

### How large is SFA Therapeutics?
SFA Therapeutics currently employs 4 people.

### What are the latest developments at SFA Therapeutics?
In March 2025, SFA Therapeutics announced positive Phase 1b data for SFA-002 in psoriasis, meeting the primary safety endpoint with no treatment-related adverse events. In August 2025, the company was nominated for the 2025 Prix Galien USA Best Startup award.

## Tags

healthtech, saas, north-america, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*